PT1143955E - Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete - Google Patents

Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete

Info

Publication number
PT1143955E
PT1143955E PT99964313T PT99964313T PT1143955E PT 1143955 E PT1143955 E PT 1143955E PT 99964313 T PT99964313 T PT 99964313T PT 99964313 T PT99964313 T PT 99964313T PT 1143955 E PT1143955 E PT 1143955E
Authority
PT
Portugal
Prior art keywords
diabetes
treatment
combination
insulin
insulin sensitizers
Prior art date
Application number
PT99964313T
Other languages
English (en)
Inventor
Mark D Erion
Vanpoelje Paul
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of PT1143955E publication Critical patent/PT1143955E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
PT99964313T 1998-12-24 1999-12-22 Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete PT1143955E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
PT1143955E true PT1143955E (pt) 2005-11-30

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99964313T PT1143955E (pt) 1998-12-24 1999-12-22 Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete

Country Status (25)

Country Link
EP (1) EP1143955B1 (pt)
JP (1) JP2003515523A (pt)
KR (3) KR100689943B1 (pt)
CN (3) CN1714866A (pt)
AT (1) ATE300288T1 (pt)
AU (1) AU771039B2 (pt)
BR (1) BR9917005A (pt)
CA (1) CA2354053A1 (pt)
CZ (1) CZ20012353A3 (pt)
DE (1) DE69926400T2 (pt)
DK (1) DK1143955T3 (pt)
ES (1) ES2246586T3 (pt)
HK (1) HK1046863B (pt)
HU (1) HUP0402506A3 (pt)
ID (1) ID30237A (pt)
IL (2) IL143569A0 (pt)
MX (1) MXPA01006511A (pt)
NO (1) NO20013115L (pt)
NZ (1) NZ512219A (pt)
PL (1) PL352756A1 (pt)
PT (1) PT1143955E (pt)
RU (2) RU2227749C2 (pt)
SK (1) SK9172001A3 (pt)
WO (1) WO2000038666A2 (pt)
ZA (1) ZA200105016B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU761267C (en) 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
SK8892002A3 (en) 1999-12-22 2003-04-01 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
ATE350385T1 (de) 2000-03-08 2007-01-15 Metabasis Therapeutics Inc Neue aryl fructose-1,6-bisphosphatase inhibitoren
CN101301294A (zh) * 2000-07-06 2008-11-12 症变治疗公司 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
EP1504014B1 (en) 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
EP1532157A4 (en) 2002-05-13 2009-02-25 Metabasis Therapeutics Inc NEW PRODRUGS FROM PMEA TO PHOSPHONIC ACID BASE AND ITS ANALOG
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
BRPI0407403B1 (pt) * 2003-02-11 2022-07-19 Cancer Research Technology Ltd Compostos de isoxazol e composição farmacêutica
PT1700856E (pt) * 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
US20070225259A1 (en) * 2004-08-18 2007-09-27 Qun Dang Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
EP1857118A1 (en) * 2004-12-13 2007-11-21 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
TW200633702A (en) * 2004-12-15 2006-10-01 Sankyo Co Medicinal composition containing fbpase inhibitor
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6110903A (en) * 1997-03-07 2000-08-29 Sankyo Company Ltd. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
DE69926400T2 (de) 2006-05-24
HK1046863B (zh) 2008-07-25
BR9917005A (pt) 2002-04-02
NO20013115L (no) 2001-08-24
HUP0402506A3 (en) 2007-05-29
NO20013115D0 (no) 2001-06-21
EP1143955A3 (en) 2002-08-28
HUP0402506A2 (hu) 2005-04-28
KR20070046210A (ko) 2007-05-02
HK1046863A1 (en) 2003-01-30
CN101164618A (zh) 2008-04-23
JP2003515523A (ja) 2003-05-07
NZ512219A (en) 2004-12-24
ES2246586T3 (es) 2006-02-16
CN100352505C (zh) 2007-12-05
AU2058300A (en) 2000-07-31
CN1714866A (zh) 2006-01-04
ATE300288T1 (de) 2005-08-15
CN1350466A (zh) 2002-05-22
MXPA01006511A (es) 2004-03-19
KR100689943B1 (ko) 2007-03-08
EP1143955B1 (en) 2005-07-27
WO2000038666A2 (en) 2000-07-06
DK1143955T3 (da) 2005-11-14
SK9172001A3 (en) 2002-04-04
EP1143955A2 (en) 2001-10-17
KR20060114724A (ko) 2006-11-07
CZ20012353A3 (cs) 2001-12-12
DE69926400D1 (de) 2005-09-01
ZA200105016B (en) 2002-09-19
ID30237A (id) 2001-11-15
RU2227749C2 (ru) 2004-04-27
IL143569A (en) 2006-06-11
PL352756A1 (en) 2003-09-08
RU2003132054A (ru) 2005-04-20
CA2354053A1 (en) 2000-07-06
KR20010099942A (ko) 2001-11-09
IL143569A0 (en) 2002-04-21
WO2000038666A3 (en) 2001-11-29
AU771039B2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
ATE413386T1 (de) Ppar-gamma modulatoren
MXPA02001099A (es) Compuestos para modular el receptor rage.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
AR045144A1 (es) Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo
IL186356A0 (en) Method of treating of preventing type-2 diabetes
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
BRPI0408984A (pt) método para tratar uma condição de doença mediada por células neutrofìlicas em um paciente, e, uso de um composto de ligação de histamina
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу
ECSP982539A (es) INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCER